Artemis Therapeutics presented data on its lead candidate artemisone, showing the drug effectively prevents human cytomegalovirus replication, at the 2018 annual meeting of the American Society for Microbiology. Artemisone is being developed as a first-in-class CMV treatment but also as a best-in-class malaria treatment.
Celltrion Healthcare, an affiliate of biopharmaceutical firm Celltrion, revealed that Truxima, or rituximab, a biosimilar for Roche's Mabthera, is being marketed in 18 European countries since its commercial launch in the UK last year. Truxima, an antibody biosimilar, was developed to treat rheumatoid arthritis and non-Hodgkin lymphoma, among other conditions.
Amgen's supplemental new drug application for the addition of overall survival data to the label of relapsed or refractory multiple myeloma drug Kyprolis, or carfilzomib, was approved by the FDA. The data were from the late-stage ASPIRE study in which the drug, combined with lenalidomide and dexamethasone, significantly reduced the death risk of patients by 21% and extended overall survival by 7.9 months compared with lenalidomide and dexamethasone alone.
Anna Pyayt, assistant professor of chemical and biomedical engineering at the University of South Florida, hit upon the idea of a mobile blood test lab that leverages two advanced technologies. Smartphones with their processing power and excellent cameras and Arduino microcontrollers and quick prototyping allowed her to produce a compact system that closely mimics its much larger counterpart.
DNA testing of tumor tissue has quickly gained traction to become the new standard of practice for personalizing colorectal cancer treatment, especially for metastatic disease. This piece delves into five guideline statements on specific tumor tissue biomarkers and mismatch repair testing for colorectal tumor tissue.
The CDC said in Morbidity and Mortality Weekly Report that people who inject drugs were 16 times more likely to develop an invasive methicillin-resistant Staphylococcus aureus infection than non-users. MRSA "is on the skin, and as the needle goes into the skin, it brings the bacteria with it," the CDC's Dr. Isaac See said.
FibroGen has completed enrollment for its late-stage study of roxadustat as a treatment for chronic kidney disease-associated anemia in patients who are and are not dependent upon dialysis, with top-line results expected in the first half of 2019.
Health authorities in Angola have reported 1.5 million cases of malaria, including 3,853 deaths, in the first half of this year. The numbers were particularly high in the provinces of Cuanza Norte, Bengo and Huambo.
Tricida on Monday launched an initial public offering
intending to raise $150 million to fund commercialization of its lead candidate TRC101 for the treatment of late-stage chronic kidney disease. Hours after the filing, Tricida announced data from its Phase III trial that tested the drug's safety and efficacy in 217 CKD patients with metabolic acidosis, showing that after 12 weeks of treatment, 59.2% of recipients experienced an increase in blood bicarbonate, versus 22.5% of the placebo group.
A total of 1,112 people, including all known contacts of all patients confirmed to have contracted the Ebola virus in the city of Mbandaka in the Democratic Republic of Congo, have been immunized with Merck's VSV-EBOV vaccine, with the outbreak total now reaching 53 cases. Meanwhile, the Trump administration has dropped a plan to slash $252 million in leftover funding to combat Ebola in Africa.